The following listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (previously presented) A stable G-CSF formulation containing one or more amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid, glutamic acid, threonine and asparagine; one or more amino acids selected from hydrophobic amino acids; and methionine.

2. (previously presented) The G-CSF formulation of claim 1 having a residual ratio of G-CSF of 90% or more after long-term storage testing at 25°C for 3 months or a residual ratio of G-CSF of 90% or more after long-term storage testing at 40°C for 2 months or a residual ratio of G-CSF of 90% or more after accelerated testing at 50°C for 1 month or a residual ratio of G-CSF of 90% or more after accelerated testing at 60°C for 2 weeks and a content of Met-oxidized G-CSF of 1% or less after accelerated testing at 50°C for 1 month or after accelerated testing at 60°C for 2 weeks.

3. (previously presented) The G-CSF formulation of claim 1 wherein said hydrophobic amino acid is selected from phenylalanine, tryptophan and leucine.

4. (previously presented) The G-CSF formulation of claim 1 containing one or more amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid and

glutamic acid; one or more amino acids selected from the group consisting of phenylalanine, tryptophan and leucine; and methionine.

5. (previously presented) The G-CSF formulation of claim 1 containing phenylalanine, arginine and methionine.

6. (previously presented) The G-CSF formulation of claim 1, which is substantially free from protein as a stabilizer.

7. (previously presented) The G-CSF formulation of claim 1 in the form of a lyophilized formulation.

8. (previously presented) The G-CSF formulation of claim 1 further containing mannitol.

9. (previously presented) The G-CSF formulation of claim 1 further containing a surfactant.

10. (previously presented) The G-CSF formulation of claim 9 wherein said surfactant is a polyoxyethylene sorbitan alkyl ester.

11. (previously presented) The G-CSF formulation of claim 10 wherein said surfactant is Polysorbate 20 and/or 80.

12. (previously presented) The G-CSF formulation of claim 1, which has a pH of 5-7.

13. (previously presented) The G-CSF formulation of claim 12, which has a pH of 5.5-6.8.

14. (previously presented) The G-CSF formulation of claim 13, which has a pH of 6.5.

15. (previously presented) The G-CSF formulation of claim 1 wherein G-CSF is produced from CHO cells.

16. (previously presented) A stable G-CSF formulation having a residual ratio of G-CSF of 90% or more after long-term storage testing at 25°C for 3 months or a residual ratio of G-CSF of 90% or more after long-term storage testing at 40°C for 2 months or a residual ratio of G-CSF of 90% or more after accelerated testing at 50°C for 1 month or a residual ratio of G-CSF of 90% or more after accelerated testing at 60°C for 2 weeks, characterized in that it contains one or more amino acids selected from the group consisting of lysine, histidine, aspartic acid, glutamic acid, threonine and asparagine; and one or more amino acids selected from hydrophobic amino acids; and it has a pH of 5-7.

17. (previously presented) A stable G-CSF formulation according to claim 16, characterized in that it contains one or more amino acids selected from the group consisting of lysine, histidine, aspartic acid and glutamic acid; and one or more amino acids selected from the group consisting of phenylalanine, tryptophan and leucine; and it has a pH of 5-7.

18. (previously presented) A stable G-CSF formulation having a residual ratio of G-CSF of 90% or more after long-term storage testing at 25°C for 3 months or a residual ratio of G-CSF of 90% or more after long-term storage testing at 40°C for 2 months or a residual ratio of G-CSF of 90% or more after accelerated testing at 50°C for 1 month or a residual ratio of G-CSF of 90% or more after accelerated testing at 60°C for 2 weeks, characterized in that it contains one or more amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid, glutamic acid, threonine and asparagine; and one or more amino acids selected from the group consisting of tryptophan and leucine; and it has a pH of 5-7.

19. (previously presented) A stable G-CSF formulation according to claim 18, characterized in that it contains one or more amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid and glutamic acid; and one or more amino acids selected from the group consisting of tryptophan and leucine; and it has a pH of 5-7.

20. (previously presented) The G-CSF formulation of claim 16 or 18, which has a pH of 6.5.

Claims 21-30 (cancelled).